Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: An exploratory analysis of NRG oncology/gynecologic oncology group trials 179 and 204

International Journal of Gynecological Cancer

Volumn 25, Issue 2, 2015, Pages 303-308

  Chase, Dana M ^a   Kauderer, James ^b   Wenzel, Lari ^c   Ramondetta, Lois ^d   Cella, David ^e   Long, Harry J ^f   Monk, Bradley J ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Cervical cancer; Grade 3; Grade 4; Gynecologic oncology group; Quality of life; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN PLUS PACLITAXEL; CISPLATIN PLUS TOPOTECAN; CISPLATIN PLUS VINORELBINE; NAVELBINE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGE; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONSTIPATION; DECREASED APPETITE; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY CERVIX SCORE; FUNCTIONAL STATUS; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; ODOR; PAIN; PERIPHERAL NEUROPATHY; PERSONAL APPEARANCE; PREDICTIVE VALUE; PREMEDICATION; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL DISEASES; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DISEASE PROGRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS;

EID: 84925850311     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000328     Document Type: Article

References (16)

1. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
2. Barrett-Lee P, Bokemeyer C, Gascón P, et al. ECAS Advisory Board and Participating Centers. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist. 2005;10:743-757.
3. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9(suppl 5):31-40.
4. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol. 2007; 5(2 suppl 1):5-12.
5. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology. 2007;21:946.
6. Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
7. Ettinger DS, Bierman PJ, Bradbury B, et al. National Comprehensive Cancer Network (NCCN). Antiemesis. J Natl Compr Canc Netw. 2007;5:12-33.
8. Huang HQ, Brady MF, Cella D, et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007;17:387-393.
9. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6:5.
10. Lee CK, Stockler MR, Coates AS, et al. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer. 2010;102:1341-1347.
11. Argyriou AA, Polychronopoulos P, Koutras A, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer. 2006;14:223-229.
12. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy: Could it be predicted? Support Care Cancer. 2005;13:647-651.
13. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633.
14. Chase DM, Huang HQ, Wenzel L, et al. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:315-319.
15. Cortejoso L, García MI, García-Alfonso P, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013;71:1463-1472.
16. Del Fabbro E, Dev R, Hui D, et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31:1271-1276.